NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$84.45

-0.31 (-0.37 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$83.86

▼

$84.49

50-Day Range

$67.89

▼

$84.76

52-Week Range

$63.22

▼

$84.94

Volume789,000 shs

Average Volume989,545 shs

Market Capitalization$198.86 billion

P/E Ratio29.32

Dividend Yield1.57%

Beta0.42

30 days | 90 days | 365 days | Advanced Chart

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

3 European Stocks to Buy for International Exposure (NVO)
May 25, 2021 | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Reaches New 12-Month High at $82.55
June 8, 2021 | americanbankingnews.com

Novo Nordisk A/S (NYSE:NVO) Sees Unusually-High Trading Volume
June 7, 2021 | americanbankingnews.com

Novo’s Wegovy Approved After Superior Weight-Loss Impact Shown
June 7, 2021 | msn.com

Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
June 4, 2021 | finance.yahoo.com

UPDATE 2-U.S. FDA approves Novo Nordisk's semaglutide as obesity treatment
June 4, 2021 | finance.yahoo.com

FDA approves Novo Nordisk’s obesity drug Wegovy, which helped people cut weight 15%
June 4, 2021 | finance.yahoo.com

Novo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment
June 1, 2021 | finance.yahoo.com

Novo Nordisk A/S : Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
May 29, 2021 | markets.businessinsider.com

Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
May 28, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:NVO
Previous Symbol
CUSIPN/A
CIK353278
Webwww.novonordisk.com
Phone45-4444-8888
Employees45,323
Year Founded1923

Sales & Book Value

Annual Sales$19.45 billion
Price / Sales10.23
Cash Flow$3.10 per share
Price / Cash Flow27.20
Book Value$4.12 per share
Price / Book20.50

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares2,354,800,000
Market Cap$198.86 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

1.42 out of 5 stars

Medical Sector

991st out of 2,099 stocks

Pharmaceutical Preparations Industry

487th out of 831 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Novo Nordisk A/S.

2.1 Community Rank

Outperform Votes
Novo Nordisk A/S has received 349 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Novo Nordisk A/S has received 463 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Novo Nordisk A/S has received 57.02% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote “Outperform” if you believe NVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Novo Nordisk A/S pays a meaningful dividend of 1.57%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Novo Nordisk A/S has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Novo Nordisk A/S is 48.19%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 39.12% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.07% of the stock of Novo Nordisk A/S is held by insiders.
Percentage Held by Institutions
Only 5.72% of the stock of Novo Nordisk A/S is held by institutions.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Novo Nordisk A/S are expected to grow by 8.97% in the coming year, from $3.12 to $3.40 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novo Nordisk A/S is 29.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 29.86.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novo Nordisk A/S is 29.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 43.44.
Price to Earnings Growth Ratio
Novo Nordisk A/S has a PEG Ratio of 3.07. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Novo Nordisk A/S has a P/B Ratio of 20.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

Is Novo Nordisk A/S a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S or view top-rated stocks.

What stocks does MarketBeat like better than Novo Nordisk A/S?

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Novo Nordisk A/S.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Tuesday, May, 4th. The company reported $5.45 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.81 by $4.64. The business had revenue of $5.48 billion for the quarter, compared to analysts' expectations of $5.02 billion. Novo Nordisk A/S had a net margin of 33.77% and a trailing twelve-month return on equity of 71.90%.
View Novo Nordisk A/S's earnings history.

How has Novo Nordisk A/S's stock price been impacted by COVID-19 (Coronavirus)?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVO shares have increased by 45.9% and is now trading at $84.45.
View which stocks have been most impacted by COVID-19.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a semi-annual dividend on Tuesday, February 23rd. Investors of record on Monday, March 29th will be paid a dividend of $0.9494 per share on Wednesday, April 7th. This represents a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, March 26th. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.78.
View Novo Nordisk A/S's dividend history.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $1.33 per share and currently has a dividend yield of 1.56%. Novo Nordisk A/S does not yet have a strong track record of dividend growth. The dividend payout ratio of Novo Nordisk A/S is 48.19%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 39.12% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:

Mr. Lars Fruergaard Jorgensen, Pres, CEO & Member of Management Board (Age 55, Pay $5.82M) (LinkedIn Profile)
Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 50, Pay $2.15M) (LinkedIn Profile)
Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 51, Pay $2.27M) (LinkedIn Profile)
Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 49, Pay $2.15M) (LinkedIn Profile)
Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 48, Pay $1.63M) (LinkedIn Profile)
Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 51) (LinkedIn Profile)
Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 55) (LinkedIn Profile)
Mr. Ludovic Helfgott, Exec. VP, Head of Biopharm & Member of Management Board (Age 47) (LinkedIn Profile)
Mr. Martin Holst Lange, Exec. VP, Head of Devel. & Member of the Management Board
Mr. Marcus Schindler Ph.D., Exec. VP of Research & Early Devel., CSO and Member of the Management Board (Age 55)

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Novo Nordisk A/S's key competitors?

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche (RHHBY), Pfizer (PFE), Eli Lilly and (LLY), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Merck & Co., Inc. (MRK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS) and Regeneron Pharmaceuticals (REGN).
View all of NVO's competitors.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.06%), Fisher Asset Management LLC (0.68%), Loomis Sayles & Co. L P (0.28%), Capital International Investors (0.22%), Fayez Sarofim & Co (0.21%) and Folketrygdfondet (0.18%).
View institutional ownership trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Folketrygdfondet, Amundi Asset Management US Inc., Mirae Asset Global Investments Co. Ltd., Morgan Stanley, Avalon Investment & Advisory, Eaton Vance Management, and GW Henssler & Associates Ltd..
View insider buying and selling activity for Novo Nordisk A/S or view top insider-selling stocks.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Optiver Holding B.V., Optiver Holding B.V., BlackRock Inc., Alyeska Investment Group L.P., Capital International Investors, Millennium Management LLC, Fisher Asset Management LLC, and Stifel Financial Corp.
View insider buying and selling activity for Novo Nordisk A/S or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $84.45.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S has a market capitalization of $198.86 billion and generates $19.45 billion in revenue each year. The company earns $6.46 billion in net income (profit) each year or $2.76 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

Novo Nordisk A/S employs 45,323 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?

The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., Calibrium, Churchill Stateside Solar Fund XIV LLC, Corvidia, Emisphere Technologies, MB2 LLC, NNE A/S, Novo Investment Pte Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk B.V., Novo Nordisk Biopharm Limited, Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comercio Produtos Farmaceuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungaria Kft., Novo Nordisk Inc., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZ-LLC, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Scandinavia AB, Novo Nordisk Scandinavia AS, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representacion C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, and Ziylo.

When was Novo Nordisk A/S founded?

Novo Nordisk A/S was founded in 1923.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

Where are Novo Nordisk A/S's headquarters?

Novo Nordisk A/S is headquartered at Novo Alle, Bagsvaerd G7, 2880.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]

This page was last updated on 6/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here